Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1991;84:540-549

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grines, C. L.
Right arrow Articles by DeMaria, A. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grines, C. L.
Right arrow Articles by DeMaria, A. N.

Circulation, Vol 84, 540-549, Copyright © 1991 by American Heart Association


ARTICLES

A prospective, randomized trial comparing combination half-dose tissue- type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group

CL Grines, SE Nissen, DC Booth, JC Gurley, N Chelliah, R Wolf, J Blankenship, MC Branco, K Bennett and AN DeMaria
Department of Medicine, University of Kentucky, Lexington.

BACKGROUND. The potential benefits of combination thrombolytic agents in the treatment of myocardial infarction remain uncertain. In a small pilot study, we demonstrated that combining half-dose tissue-type plasminogen activator (t-PA) with streptokinase (SK) achieved a high rate of infarct vessel patency and a low rate of reocclusion at half the cost of full-dose t-PA. METHODS AND RESULTS. We designed a prospective trial in which 216 patients were randomized within 6 hours of myocardial infarction to receive either the combination of half-dose (50 mg) t-PA with streptokinase (1.5 MU) during 1 hour or to the conventional dose of t-PA (100 mg) during 3 hours. Acute patency was determined by angiography at 90 minutes, and angioplasty was reserved for failed thrombolysis. Heparin and aspirin regimens were maintained until follow-up catheterization at day 7. Acute patency was significantly greater after t-PA/SK (79%) than with t-PA alone (64%, p less than 0.05). After angioplasty for failed thrombolysis, acute patency increased to 96% in both groups. Marked depletion of serum fibrinogen levels occurred after t-PA/SK compared with t-PA alone at 4 hours (37 +/- 36 versus 199 +/- 66 mg/dl, p less than 0.0001) and persisted 24 hours after therapy (153 +/- 66 versus 252 +/- 75 mg/dl, p less than 0.0001). Reocclusion (3% versus 10%, p = 0.06), reinfarction (0% versus 4%, p less than 0.05), and need for emergency bypass surgery (1% versus 6%, p = 0.05) tended to be less in the t-PA/SK group. Greater myocardial salvage was apparent in the t-PA/SK group as assessed by infarct zone function at day 7 (-1.9 SD/chord versus -2.3 SD/chord after t-PA alone, p less than 0.05). In-hospital mortality (6% versus 4%) and serious bleeding (12% versus 11%) were similar between the two groups. CONCLUSIONS. These results suggest that a less expensive regimen of half-dose t-PA with SK yields superior 90-minute patency and left ventricular function and a trend toward reduced reocclusion compared with the conventional dose of t-PA.


This article has been cited by other articles:


Home page
QJMHome page
Y. Dundar, R. Hill, R. Dickson, and T. Walley
Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review
QJM, February 1, 2003; 96(2): 103 - 113.
[Abstract] [Full Text] [PDF]


Home page
Behav ModifHome page
B. C. Bock, R. E. Carmona-Barros, J. L. Esler, and P. L. Tilkemeier
Program Participation and Physical Activity Maintenance after Cardiac Rehabilitation
Behav Modif, January 1, 2003; 27(1): 37 - 53.
[Abstract] [PDF]


Home page
ChestHome page
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest, January 1, 2001; 119 (2009): 253S - 277S.
[Full Text] [PDF]


Home page
NEJMHome page
R. Collins, R. Peto, C. Baigent, and P. Sleight
Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction
N. Engl. J. Med., March 20, 1997; 336(12): 847 - 860.
[Full Text] [PDF]


Home page
NEJMHome page
The GUSTO Investigators
An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
N. Engl. J. Med., September 2, 1993; 329(10): 673 - 682.
[Abstract] [Full Text]


Home page
NEJMHome page
C. L. Grines, K. F. Browne, J. Marco, D. Rothbaum, G. W. Stone, J. O'Keefe, P. Overlie, B. Donohue, N. Chelliah, G. C. Timmis, et al.
A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction
N. Engl. J. Med., March 11, 1993; 328(10): 673 - 679.
[Abstract] [Full Text]